Protaphane is a long-acting insulin and may be used alone or in combination with fast or rapid-acting insulin products.
Dosage: Dosage is individual and determined in accordance with the needs of the patient. The individual insulin requirement is usually between 0.3 and 1.0 IU/kg/day.
The daily insulin requirement may be higher in patients with insulin resistance (e.g. during puberty or due to obesity) and lower in patients with residual, endogenous insulin production.
Dosage adjustment: Concomitant illness, especially infections and feverish conditions, usually increases the patient's insulin requirement. Concomitant diseases in the kidney, liver or affecting the adrenal, pituitary or thyroid gland can require changes in the insulin dose.
Adjustment of dosage may also be necessary if patients change physical activity or their usual diet.
Dosage adjustment may be necessary when transferring patients from one insulin preparation to another.
Administration: For subcutaneous use. Insulin suspensions are never to be administered intravenously.
Protaphane is administered subcutaneously in the thigh. If convenient, the abdominal wall, the gluteal region or the deltoid region may also be used.
Subcutaneous injection into the thigh results in a slower and less variable absorption compared to the other injection sites. Injection into a lifted skin fold minimises the risk of unintended intramuscular injection. The needle should be kept under the skin for at least 6 seconds to make sure the entire dose is injected. Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy.
Protaphane vials are for use with insulin syringes with a corresponding unit scale.
Protaphane is accompanied by a package leaflet with detailed instructions for use to be followed.
Protaphane Penfill: Protaphane Penfill (cartridge) is designed to be used with Novo Nordisk delivery systems and NovoFine or NovoTwist needles.